ArticleThe European journal of neuroscience2026
Cochlear Functional Changes and CGRP Modulation in a Chronic Nitroglycerin Migraine-Like Rat Model.
Article in The European journal of neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Auditory and vestibular symptoms in vestibular migraine, cochlear migraine, and Ménière's disease overlap, yet mechanisms linking migraine biology to inner ear dysfunction remain unclear. Calcitonin gene-related peptide (CGRP) is a key mediator of trigeminovascular activation and a major therapeutic target in migraine, but its contribution to cochlear dysfunction is not well defined. Using a repeated nitroglycerin (NTG) paradigm in male Wistar rats, we investigated whether a systemic migraine-like state affects cochlear function and whether these effects are dependent on CGRP. Rats received saline, NTG, or NTG followed by the CGRP receptor antagonist olcegepant (OLC). NTG increased plasma TNF-α and elevated trigeminal c-Fos; olcegepant partially normalized these markers, whereas behavioral changes in the open-field test were interpreted cautiously because baseline immobility differed across groups before treatment. NTG produced frequency-dependent changes in distortion-product otoacoustic emissions and auditory brain stem response thresholds. Electrocochleography showed limited changes, and scala media proportions did not differ significantly among groups, indicating no evidence of overt endolymphatic hydrops at the studied time point. Inner hair-cell synaptic markers showed no significant group differences for CtBP2, whereas GluR2 puncta differed between NTG and NTG + OLC (p = 0.012). Olcegepant attenuated NTG-associated cochlear functional changes and was associated with differences in postsynaptic GluR2 puncta, alongside region-specific changes in cochlear CGRP immunoreactivity. These findings support a mechanistic link between migraine-like trigeminovascular activation and early cochlear dysfunction and suggest that CGRP receptor blockade may benefit migraine patients with cochlear or vestibular symptoms. Future studies should assess females, estrous cycle tracking, hormones, and sex-specific auditory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.